Hero image with Pittsburgh background pittplusme.org/study/1625

STUDY BASICS

Have you had atopic dermatitis (eczema) for at least 2 years? If so, you may be able to participate in a study to help determine how safe and effective a study drug, called nemolizumab, is in treating atopic dermatitis. Study participation may last up to 60 weeks and may involve up to 16 study visits. Compensation is provided.


IRB:
  20191494 - A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

RESEARCH AREAS:
  Featured Research

Age Range
AGE:   18 and up

Duration DURATION:  Up to 60 weeks
VISITS:  Up to 16

Location LOCATION: 
Falk Medical Building - Oakland
Compensation COMPENSATION: 

$45 per visit

Phone Number PHONE NUMBER:
1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1625
OR
Phone Number PHONE NUMBER:
1-866-438-8230

MEET THE RESEARCHER


Laura Ferris

Laura Korb Ferris, MD, PhD, is Associate Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.




PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet